BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Core Insights - BriaCell Therapeutics Corp. has received its fourth consecutive positive recommendation from the independent Data Safety Monitoring Board (DSMB) for its pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in patients with metastatic breast cancer [1][2][6] - The DSMB raised no safety concerns and recommended that the study continue without modifications, indicating a favorable safety profile for the BriaCell regimen [2][6] - The ongoing Phase 3 study is being conducted under Fast Track designation by the FDA, highlighting the significant unmet medical need in metastatic breast cancer [2][6] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [1][3] - The company is committed to addressing urgent medical needs for patients with metastatic breast cancer through its innovative treatment approach [3]